1376604-17-9

Upstream product

• 1376604-14-6 methyl 3-oxo-5-phenyl-2,3-dihydropyridazine-4-carboxylate 
• 1074-12-0 phenylglyoxal hydrate 
• 474381-67-4 3-oxo-5-phenyl-2,3-dihydropyridazine-4-carbonitrile 
• 6168-72-5 2-Amino-1-propanol 
• 1258614-99-1 methyl 3-chloro-5-phenylpyridazine-4-carboxylate 

Relevant academic research and scientific papers

Pyridazine derivatives, compositions and methods for treating cognitive impairment

This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of α5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.

METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5 -containing GABAA receptor agonist in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA

The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a α5 -containing GABAA receptor agonist and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some enbodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia.